MA49561A - DUAL SPECIFIC ENHANCED POLYPEPTIDIC MOLECULE - Google Patents

DUAL SPECIFIC ENHANCED POLYPEPTIDIC MOLECULE

Info

Publication number
MA49561A
MA49561A MA049561A MA49561A MA49561A MA 49561 A MA49561 A MA 49561A MA 049561 A MA049561 A MA 049561A MA 49561 A MA49561 A MA 49561A MA 49561 A MA49561 A MA 49561A
Authority
MA
Morocco
Prior art keywords
dual specific
molecule
specific enhanced
region derived
binding region
Prior art date
Application number
MA049561A
Other languages
French (fr)
Other versions
MA49561B1 (en
Inventor
Sebastian Bunk
Martin Hofmann
Dominik Maurer
Felix Unverdorben
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102017115966.5A external-priority patent/DE102017115966A1/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of MA49561A publication Critical patent/MA49561A/en
Publication of MA49561B1 publication Critical patent/MA49561B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1054—Lentiviridae, e.g. HIV, FIV, SIV gag-pol, e.g. p17, p24
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une molécule polypeptidique bispécifique comprenant une première chaîne polypeptidique et une seconde chaîne polypeptidique fournissant une région de liaison dérivée d'un récepteur de lymphocytes t (tcr) spécifique pour un épitope peptidique viral associé à un complexe majeur d'histocompatibilité (cmh), et une région de liaison dérivée d'un anticorps capable de recruter des cellules effectrices immunitaires humaines par liaison spécifique à un antigène de surface desdites cellules. L'invention concerne également des procédés de fabrication de la molécule polypeptidique bispécifique, et leurs utilisations.The present invention relates to a bispecific polypeptide molecule comprising a first polypeptide chain and a second polypeptide chain providing a binding region derived from a t-cell receptor (tcr) specific for a viral peptide epitope associated with a major histocompatibility complex (cmh ), and a binding region derived from an antibody capable of recruiting human immune effector cells by specific binding to a surface antigen of said cells. Also disclosed are methods of making the bispecific polypeptide molecule, and uses thereof.

MA49561A 2017-07-14 2018-07-13 Dual-specific enhanced polypeptide molecule MA49561B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532713P 2017-07-14 2017-07-14
DE102017115966.5A DE102017115966A1 (en) 2017-07-14 2017-07-14 Polypeptide molecule with improved dual specificity
DE102017119866 2017-08-30
US201862658318P 2018-04-16 2018-04-16
DE102018108995 2018-04-16

Publications (2)

Publication Number Publication Date
MA49561A true MA49561A (en) 2020-05-20
MA49561B1 MA49561B1 (en) 2021-05-31

Family

ID=62916686

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49561A MA49561B1 (en) 2017-07-14 2018-07-13 Dual-specific enhanced polypeptide molecule

Country Status (1)

Country Link
MA (1) MA49561B1 (en)

Also Published As

Publication number Publication date
MA49561B1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
MA46299B1 (en) Improved dual specificity polypeptide molecule
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
MA45309B1 (en) Transfected t cells and t cell receptors for use in immunotherapy against cancers
WO2021097365A3 (en) Antigen-binding proteins targeting shared neoantigens
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
MX2021003608A (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously.
MX2021009274A (en) Half-life extended immtac binding cd3 and a hla-a*02 restricted peptide.
TR201905437T4 (en) Bifunctional polypeptides.
MA31093B1 (en) vaccine.
MX357944B (en) Antibody variants and uses thereof.
UY31433A1 (en) NEW SPECIFIC ANTIBODIES OF PEPTIDES - AMILOIDS AND THEIR USES AS AGENTS OF DIAGNOSIS OR DRUGS
IL148113A0 (en) Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
WO2006044410A3 (en) A32 monoclonal antibody fusion proteins for use as hiv inhibitors and vaccines
MX2022016192A (en) Conditionally active anti-nectin-4 antibodies.
WO2020016661A3 (en) Antibodies specific to folate receptor alpha
MX2021012365A (en) Bispecific antibodies.
MA49561A (en) DUAL SPECIFIC ENHANCED POLYPEPTIDIC MOLECULE
AR112228A1 (en) POLYPEPTIDE MOLECULE WITH ENHANCED DUAL SPECIFICITY
MX2022003432A (en) Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability.
WO2018232278A3 (en) Phospho-rab antibodies, assays and methods of use thereof
WO2017075045A3 (en) Antibodies to b7-h1
PH12020500095A1 (en) Improved dual specific polypeptide molecule
EA202090250A1 (en) IMPROVED DOUBLE SPECIFICITY POLYPEPTIDE MOLECULE
EP3636668A3 (en) Immunoglobulins directed to bacterial viral and endogenous polypeptides